Literature DB >> 15258777

Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients.

Hideharu Funatsu1, Hidetoshi Yamashita, Hidetaka Noma, Tatsuya Mimura, Shinko Nakamura, Kumi Sakata, Sadao Hori.   

Abstract

BACKGROUND: Cytokine levels are elevated in the ocular fluid of diabetic patients. It is unclear whether aqueous humor levels of vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) are related to the vitreous fluid levels of these substances and to the progression of diabetic retinopathy.
METHODS: Aqueous humor and vitreous fluid samples were obtained during cataract and vitreous surgery from ten eyes of ten patients with diabetic macular edema and 26 eyes of 26 patients with proliferative diabetic retinopathy (PDR). The VEGF and IL-6 levels in aqueous humor, vitreous fluid, and plasma were measured by enzyme-linked immunosorbent assay.
RESULTS: VEGF and IL-6 levels in aqueous humor were significantly correlated with those in vitreous fluid (rho=0.793 and rho=0.737, respectively). VEGF levels in aqueous humor and vitreous fluid were significantly correlated with the corresponding IL-6 levels (rho=0.631 and rho=0.687, respectively). The aqueous and vitreous levels of VEGF were significantly correlated with the severity of diabetic retinopathy (rho=0.659 and rho=0.771, respectively). Aqueous and vitreous levels of IL-6 were also significantly correlated with the severity of diabetic retinopathy (rho=0.742 and rho=0.746, respectively). Aqueous and vitreous levels of both VEGF and IL-6 were significantly higher in the patients with active PDR than those in quiescent PDR.
CONCLUSIONS: Our results suggest that there is a significant relationship between VEGF and IL-6 levels in aqueous humor and in vitreous fluid. Measurement of the aqueous levels of VEGF and IL-6 may be useful to analyze the pathogenesis of diabetic retinopathy and to predict disease activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258777     DOI: 10.1007/s00417-004-0950-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  21 in total

1.  Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy.

Authors:  H Funatsu; H Yamashita; E Shimizu; R Kojima; S Hori
Journal:  Retina       Date:  2001       Impact factor: 4.256

2.  Regulation of vascular endothelial growth factor expression by insulin-like growth factor I.

Authors:  R S Punglia; M Lu; J Hsu; M Kuroki; M J Tolentino; K Keough; A P Levy; N S Levy; M A Goldberg; R J D'Amato; A P Adamis
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

3.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

4.  IL-6 increases endothelial permeability in vitro.

Authors:  N Maruo; I Morita; M Shirao; S Murota
Journal:  Endocrinology       Date:  1992-08       Impact factor: 4.736

5.  Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment.

Authors:  P L Lip; F Belgore; A D Blann; M W Hope-Ross; J M Gibson; G Y Lip
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

6.  Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.

Authors:  L P Aiello; S E Bursell; A Clermont; E Duh; H Ishii; C Takagi; F Mori; T A Ciulla; K Ways; M Jirousek; L E Smith; G L King
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

7.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

8.  Interleukin-6 (IL-6) gene expression and secretion by cytokine-stimulated human retinal pigment epithelial cells.

Authors:  V M Elner; W Scales; S G Elner; J Danforth; S L Kunkel; R M Strieter
Journal:  Exp Eye Res       Date:  1992-03       Impact factor: 3.467

9.  Hepatocyte growth factor in vitreous fluid of patients with proliferative diabetic retinopathy and other retinal disorders.

Authors:  Y Katsura; T Okano; M Noritake; H Kosano; H Nishigori; S Kado; T Matsuoka
Journal:  Diabetes Care       Date:  1998-10       Impact factor: 19.112

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  104 in total

Review 1.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

2.  Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.

Authors:  L Nicholson; N V Patrao; J Ramu; C Vazquez-Alfageme; M Muwas; R Rajendram; P G Hykin; S Sivaprasad
Journal:  Eye (Lond)       Date:  2017-04-28       Impact factor: 3.775

3.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

4.  Variability of disease activity in patients treated with ranibizumab for neovascular age-related macular degeneration.

Authors:  P Enders; P Scholz; P S Muether; S Fauser
Journal:  Eye (Lond)       Date:  2016-05-20       Impact factor: 3.775

5.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

6.  Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy.

Authors:  Kocabora M Selim; Durmaz Sahan; Taskapili Muhittin; Cekic Osman; Ozsutcu Mustafa
Journal:  Indian J Ophthalmol       Date:  2010 Sep-Oct       Impact factor: 1.848

7.  Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate.

Authors:  Koji M Nishiguchi; Keiko Kataoka; Shu Kachi; Keiichi Komeima; Hiroko Terasaki
Journal:  PLoS One       Date:  2010-10-20       Impact factor: 3.240

8.  Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy.

Authors:  Yong Woon Shin; Yoon Jung Lee; Byung Rho Lee; Hee Yoon Cho
Journal:  Korean J Ophthalmol       Date:  2009-12-04

9.  Intravitreal bevacizumab in the treatment of neovascular glaucoma secondary to central retinal vein occlusion: a case report.

Authors:  Tarek Alasil; Michael E Rauser
Journal:  Cases J       Date:  2009-10-30

10.  Effect of intraocular surgery and ketamine on aqueous and serum cytokines.

Authors:  Kyaw Lin Tu; Stephen B Kaye; Gediminas Sidaras; William Taylor; Alan Shenkin
Journal:  Mol Vis       Date:  2007-07-12       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.